About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, October 25th, 2012

The QualityStocks
Daily Stock List

graphic
graphic

Bergamo Acquisition Corp. (BGMO)

Stock Guru, Bold Stocks, OTC Picks, HyperGrowthStock, and PennyTrader Publisher reported previously on Bergamo Acquisition Corp. (BGMO), and we are highlighting the Company as "One to Watch" here at the QualityStocks Daily Newsletter.

Incorporated in 1997, Bergamo Acquisition Corp. is a global investor with corporate headquarters in Henderson, Nevada, in addition to affiliated offices in Europe and Asia. The Company is targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other investors. Bergamo has engaged investments in financial instruments and companies around the world.

In May 2012, Bergamo purchased 100 percent interest in a European entity for its investing strategies utilizing the EURO currency. Bergamo Acquisition reported net income of $88,439,000 for the period ending September 17, 2012.

In addition, the Company (as a source of funding) will work alongside company management in effecting management buy-outs, friendly mergers and value-accretive capital projects. Occasionally, Bergamo may provide debt financing as a proprietary investor in the form of bi-laterally negotiated private placements. Bergamo has taken a 60 percent interest in Bergamo Energy, Inc. of Miami. Bergamo Energy is a provider of solar energy technologies to sovereign and corporate customers in the Asian markets.

Concerning Renewable Energy products, Bergamo Acquisition is pursuing alternate energy projects in developing and underdeveloped countries with their innovative products. These products include solar generators for cell phone towers, solar generators for home and industries, and tube well water pumping solar systems.

Pertaining to Hybrid Solar Thermal Power Plants, the Company offers Vertical Integration of Clean Energy. They deliver energy projects from concept through completion with a vertical portfolio of projects. These include design, construction management and facility maintenance services. They source and provide equipment and develop technology. They offer turnkey solutions to developers, utilities, water districts, power plant owners and industrial customers looking to diversify and complement their existing generation portfolio with compact solar thermal generation. Their Bergamo Energy develops high efficiency state-of-the art combined cycle power plants, together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules.

The design of a 5 MW Hybrid Solar Thermal Power Plant is to produce over 40 Gwh of base load power with an over-sized solar field yielding a 25 percent capacity factor. When in operation they will be able to provide power for up to 20,000 average homes. Advanced Hybrid Solar Thermal Power Plants can deliver base load power with Hybrid fuel flexibility. The operational life of these power plants can exceed 50 years. Each 5 MW CSP plant can provide up to 250,000 gallons daily of potable water from a brackish or seawater source together with electricity generation.

We're tracking Bergamo Acquisition Corp. (BGMO) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Bergamo Acquisition Corp. (BGMO), closed Thursday's trading session at $0.0182, down 1.62%, on 19,550 volume with 4 trades. The average volume for the last 60 days is 397,057 and the stock's 52-week low/high is $0.0136/$0.07.

Axcelis Technologies, Inc. (ACLS)

OTCPicks, StreetAuthority Daily, Stock Fortune Teller, PennyStockVille, PennyInvest, StockEgg, and CoolPennyStocks reported earlier on Axcelis Technologies, Inc. (ACLS), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Beverly, Massachusetts, Axcelis Technologies, Inc. provides innovative, high-productivity solutions for the semiconductor industry. Their commitment is to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation and cleaning systems. Chipmakers around the world rely on Axcelis' tools and process expertise to form the transistors that power all electronics - from smartphones and laptops, to cameras, personal music players and more.

The Company manufactures their equipment at one central location in the U.S. They support their customers with a worldwide network of 30 field offices in 12 countries. Pertaining to their Global Support Solutions, they provide Field Service, Applications Support, Support Services, Continuous Improvement, Engineering/Upgrades, Global Parts Planning and Logistics, and Training.

Axcelis' equipment portfolio consists of a suite of manufacturing technologies for ion implantation and cleaning/dry strip processes. These are two of the most critical steps in IC manufacturing. In addition, the Company provides extensive aftermarket service and support. This includes spare parts, equipment upgrades, maintenance services, and customer training. More than 3,000 of their products are in use worldwide.

Last month, Axcelis Technologies announced that they signed a five-year, comprehensive global support contract, valued at $30 million, with one of the world's leading semiconductor manufacturers. The design of the Company's award winning Global Support Solutions program is to optimize all aspects of manufacturing performance throughout the fab cycle, enabling customers to achieve their business goals. With this contract, they will support a full suite of Axcelis implant, cleaning and thermal processing equipment at multiple fabs in the U.S.

This week, Axcelis Technologies announced that Mary Puma, Chairman and CEO, and Jay Zager, Executive Vice President and CFO, would present at the Piper Jaffray Technology, Media and Telecommunications Conference at the Le Parker Meridien in New York, New York on Tuesday, November 6, 2012.  The presentation, scheduled for 4:30 pm ET, will be webcast live and can be accessed on the Investor Relations section of the Company's website, www.axcelis.com.  An audio archive of the presentation will also be available on the website for 90 days.

Axcelis Technologies, Inc. (ACLS), closed Thursday's trading session at $0.91, down 0.51%, on 406,728 volume with 661 trades. The average volume for the last 60 days is 390,760 and the stock's 52-week low/high is $0.7113/$2.04.

As Seen On TV, Inc. (ASTV)

Information Solutions Group, Stock Alert, SmallCapVoice, Lebed.biz, and WallStreetGrand reported earlier on As Seen On TV, Inc. (ASTV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

As Seen On TV, Inc. identifies, develops, and markets consumer products for worldwide distribution by way of TV, Internet and retail channels. Mr. Kevin Harrington, the Company's Chairman is widely regarded as the patriarch of the direct response television industry. Mr. Harrington pioneered the house wares industry in the late 1980's with the original Food Saver.  As Seen On TV is a direct response marketing company and owner of AsSeenOnTV.com. The Company has their corporate headquarters in Clearwater, Florida. As Seen On TV's shares trade on the OTCQB.

As Seen On TV currently offers hundreds and hundreds of As Seen On TV products and other specialty items. AsSeenOnTV.com is the largest online shopping site. Their commitment is to bringing their customers the best "As Seen On TV" products at the fairest price on the Internet. Moreover, AsSeenOnTV.com searches worldwide to bring their customers a broad spectrum of other quality products.

As Seen On TV is the parent company for TVGoods, Inc., a Direct Response marketing organization. The Company's strategy employs three primary channels: Direct Response Television (Infomercials), Television Shopping Networks and Retail Outlets. TVGoods offers entrepreneurs a turnkey solution enabling entrepreneurs to introduce products to the consumer market. The Management of TVGoods is responsible for the first-ever fishing infomercial with the Flying Lure, the first-ever music infomercial with Wolfman Jack, and the first-ever and longest-running golf infomercial with the Medicus Golf Club.

In September, As Seen On TV announced that they launched their DRTV campaign for SeasonAire, their new 6-in-1 all-season appliance. Talk show host/TV pitchman Montel Williams hosts the long-form infomercial. The SeasonAire combines an infrared heater, a true-HEPA air filter, a UV air purifier, an ionic air freshener, a humidifier and a dual-speed cooling fan. The infrared heater warms a room as large as 1,000 square feet. The SeasonAire features on-board touch controls with an LED display, a remote control, a cool-to-touch exterior and tip-over auto shutoff. SeasonAire provides energy efficiency and long-term cost effectiveness.

As Seen On TV, Inc. (ASTV), closed Thursday's session at $0.68, up 1.19%, on 8,500 volume with 3 trades. The average volume for the last 60 days is 14,493 and the stock's 52-week low/high is $0.15/$1.50.

Aguila American Gold Ltd. (AGL.V)

We are highlighting Aguila American Gold Ltd. (AGL.V), here at the QualityStocks Daily Newsletter.

Aguila American Gold Ltd. is an emerging gold exploration company whose shares trade on the TSX Venture Exchange. The Company is focusing on advancing and developing their flagship prospective gold project - Angostura. Angostura is 180 kilometers southwest of the city of Cuzco, in southwestern Peru. Angostura is located in a prolific mineral trend, approximately 25km from the Las Bambas Mine; a $4.5 billion mineral production project undergoing development by Xstrata Mining Pty. Aguila American Gold has their headquarters in Vancouver, British Columbia,
 
The Angostura Project is in the Andean Cordillera in southern Peru, Department of Apurimac in the Garu Province. This is a prolific Gold, Copper Mining/Exploration district. Angostura is a highly prospective, rapid growth gold exploration asset containing eight titled concessions consisting of 8,644 ha.

The target system is a silica-rich epithermal gold system with a high content of iron and manganese oxides. The exploration focus is Zone One and Two, identified as Gold and Silver bearing. Zone No.1 has a surface strike 30 meters wide and 150 meters long. At Zone No.2, east of Zone No.1, the focus is exploration and artisanal mining. This zone has a surface strike 75 meters wide and 200 meters long.

In March 2012, Aguila American Gold announced that they reached a formal and legal agreement with the community of Mollepina on their wholly owned Angostura gold project. The Agreement formally allows Aguila to proceed with the advancement of their 100 percent owned, Angostura gold project. The initial term of the Agreement is for two years where Aguila American Gold has agreed to maximize local employment and assist in certain enhancements.

Today, Aguila American Gold announced that drilling has began at their Angostura gold project. The drill camp has been completed along with 7 drill pads of the permitted 20, in preparation of the 2012 drill program. Crews will be drilling 2 x 12 hour shifts daily until the Christmas break. The Company is using a custom built, mid-sized, man-portable diamond drill capable of delivering a larger-diameter drill core.

Aguila American Gold Ltd. (AGL.V), closed Thursday's trading session at $0.19, up 5.56%, on 52,000 volume. The stock's 52-week low/high is $0.14/$0.40.

FBC Holding, Inc. (FBCD)

Whisper from Wall Street, Otcstockexchange, Simply Best Penny Stocks, Top Best Pennystocks, and VIP Penny Stocks reported this month on FBC Holding, Inc. (FBCD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FBC Holding, Inc. signed a license agreement in April 2012 with Sport Technology, Inc., a California corporation. With this agreement, the Company acquired the exclusive licensing, marketing and development rights to develop, market and sell certain products owned by Sport Technology. This includes but is not limited to, Flowboard, Flow Saucer, and Snowskate. FBC Holding lists on the OTCQB. The Company is based in New Hampshire.

In addition, FBC Holding entered into a consulting agreement with Sport Technology and Mr. Michael Kern. With this consulting agreement, Sport Technology and Mr. Kern will provide consulting services related to the development, marketing and sale of the licensed products. FBC Holding will be adding additional products; the Company is in talks with a number of other manufacturers generally in the extreme sports industry.

The Flowboard is a unique extreme sports product. It can be used by surfers and snowboarders for "out-of-the-water" and "off-the-mountain" training. The Smokey Heart 36" Flowboard and the Fighter Bomber 36" Flowboard are 7-ply Canadian rock maple decks with a wide, Patented Deep Carve System (DCS). They feature a 14-wheel, arched setup that allows a user to carve 45-degree angles with fluid, edge-to-edge motion, preventing wheel bite and bushing resistance.

The Bomb Factory Logo Pro Complete Skateboard is a professional skateboard also with 7 ply Canadian Rock maple decks, 80AB grip tape, 5" Bomb Aluminum Alloy trucks, Abec-7 Bearings, and 51mm casted Polyurethane Bomb wheels.

The Company is also marketing the Rails Pro Snowskate. It features a 31"x 8" deck, an Evo rubber grip pad, aluminum trucks, and complete Railz ski assemblies. The Rails Snowskate is a Toy model Snowskate. It comes with a 31"x 8" deck, grip pad, aluminum trucks, and Railz ski assemblies. A user can convert the Snowskate into a skateboard like a user can do with the Pro model. A user removes the skis and adds traditional skateboard wheels.

Yesterday, FBC Holding management announced that they are preparing to place their first manufacturing order for the new FBC Flowboard. Mr. Eddie Liu of Ane Company in Shenzhen, China, said, "I am very glad that we are again working with Mr. Kern and manufacturing the Flowboard, it was a great success last time and we are looking forward to working with FBC Holding to make this relaunch even better."

FBC Holding, Inc. (FBCD), closed Thursday's trading session at $0.0006, up 50.00%, on 89,439,892 volume with 140 trades. The average volume for the last 60 days is 16,952,490 and the stock's 52-week low/high is $0.0002/$0.014.

Treaty Energy Corp. (TECO)

PennyTrader Publisher, FeedBlitz, StockEgg, MadPennyStocks, PennyInvest, BullRally, StockRich, PennyStockVille, HotOTC, and CoolPennyStocks reported previously on Treaty Energy Corp. (TECO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Based in New Orleans, Louisiana, Treaty Energy Corp. is an energy company that lists on the OTCQB. The Company's focus is on utilizing strategies and techniques that maximize crude oil and natural gas recoveries in volume as well as investment dollars spent. Treaty actively engages in the process of adding substantial oil and gas properties to their assets. Their corporate goal is targeting only acquisitions of properties with production capabilities and proven reserves.

Treaty Petroleum, Inc. incorporated in Nevada on February 2006. They merged into Alternate Energy Corp. in December of 2008. The Company subsequently changed their name to Treaty Energy Corp. on January 27, 2009. Treaty Energy is building both an international Oil & Gas Operating/Production Company and a self-contained Drilling and Completion Company.

The intention of Treaty Energy's aggressive acquisition policy is to move the Company into continually stronger production. This is with initial lease projects in Louisiana, Tennessee, Kansas, Texas and then beyond, for example in Belize. They primarily concentrate on oil and gas leases located in Texas; and the Belize concession to explore for oil and gas on approximately 2 million acres in Belize located in Central America.

In September, Treaty Energy provided an update on the progress of both the San Juan #1 Well, and the San Juan #2 Well in Belize. Mr. Max Mohamed, the Company's Director of Operations in Belize, stated, "The San Juan #1 well was drilled to a total depth of 2,260 ft on September 5, 2012. Open Hole Electric logs were run on the well the next day. Upon analysis of the well log data it was determined that there are multiple 'zones of interest' in San Juan #1 at similar intervals to the San Juan #2 well."

In addition, in September, Treaty Energy announced that an additional Pulling Rig was purchased for completion of wells scheduled to be drilled in West Texas. The Company purchased a Wilson Double Drum Pulling Rig in a cash transaction valued at $185,000. The unit will be used to complete the "Nine-Well Project" (to 3,000 ft.). It will begin upon completion of the McComas #20 well that is currently being worked on.

Treaty Energy Corp. (TECO), closed Thursday's trading at $0.034, up 3.03%, on 686,845 volume with 32 trades. The average volume for the last 60 days is 1,472,514 and the stock's 52-week low/high is $0.02/$0.13.

MyEZsmokes, Inc. (XRMB)

Atomic Pennies reported recently on MyEZsmokes, Inc. (XRMB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Organized on February 20, 2004, under the laws of the State of Nevada, MyEZsmokes, Inc. engages in the manufacture, sales, and distribution of electronic cigarettes (smoke free). They offer e-cigarette starter kits, disposable e-cigarette kits, as well as re-fill cartomizers in tobacco and menthol flavors.  MyEZsmokes lists on the OTC Pink Current Information. The Company has their headquarters in San Diego, California.

MyEZsmokes' primary market strategy is to become a major player in the mass marketing of electronic cigarettes in major retail outlets throughout the U.S. The target customers for electronic cigarettes are 80 plus million people. Approximate sales of the Electronic Cigarette category reached more than 200 million in 2011. The expectation is that the industry will grow to a billion dollar industry by 2015.

The electronic cigarette looks, feels, tastes, and works like a real cigarette, without the ill effects and negatives associated with the burning of tobacco. The Company's product emits a vapor; it features no tar, no tobacco, as well as no second-hand smoke. It also has no smell and no chemicals or carcinogens. The product does contain nicotine.

In September, MyEZsmokes announced increased distribution of their Icon Vapor Electronic Cigarette to casinos and other gaming businesses in the state of California. The increase consists of greater sales to existing casino accounts and the start of distribution to new casino accounts. MyEZsmokes is focusing considerable effort on the lucrative gaming business market. Serving the needs of all of the U.S. casinos is a significant element of MyEZsmokes' strategic growth plan. Currently, there exist 58 casinos operating in California and approximately 1,500 across the U.S.

In addition, in September, MyEZsmokes announced the appointment of Mr. Vince Nelson as Director of Sales and Marketing, North America. The design of this move is to help strengthen the Company's mass-market distribution strategy for their Icon Vapor brand of electronic cigarettes. Mr. Nelson brings with him over forty years of experience executing successful sales campaigns in the mass-market sector.

MyEZsmokes, Inc. (XRMB), closed Thursday at at $1.01, up 1.00%, on 26,969 volume with 30 trades. The average volume for the last 60 days is 35,754 and the stock's 52-week low/high is $0.15/$1.30.

Hana Mining Ltd. (HMG.V)

We are reporting on Hana Mining Ltd. (HMG.V), here at the QualityStocks Daily Newsletter.

Based in Vancouver, British Columbia, Hana Mining Ltd. is an emerging international exploration and development company. The Company is developing the highly prospective Ghanzi Copper-Silver Project in Botswana, Africa. Hana Mining has agreed to acquire a 100 percent controlling interest in the Ghanzi Project - subject to TSX Venture Exchange approval.

The Ghanzi Project lands are host to extensive sediment-hosted copper-silver mineralization, suggesting the possibility for a future world-class Copper-Silver district. The Project area consists of five license blocks covering 2,149 square kilometers. The Ghanzi Project is in the center of the Kalahari Copper Belt in northwestern Botswana. The property contains sediment-hosted copper-silver deposits with a demonstrated cumulative tested strike length of 70 kilometers. This favorable geology extends over an estimated strike length of 600 kilometers.

This past May, Hana Mining released results of their most recent NI 43-101 compliant Preliminary Economic Assessment (PEA) for the Ghanzi Project. The PEA details a 10,000 tonne per day open-pit mining and milling operation at the Banana Zone and Zone 5 at an initial capital expenditure of US$285.5 million. The expectation is that this operation will produce approximately 66.4 million pounds of copper and 878,000 ounces of silver annually over a minimum 13-year mine life.

The Banana Zone (including the adjacent Chalcocite Zone) contains almost 90 percent of the total resource estimate tonnage. The Banana Zone has been the focus of the Company's drilling and development efforts since mid-2009. This zone sits in the southwest end of the license area, and is approximately 32 kilometers in length.

This week, Hana Mining announced eleven diamond drill hole results from Zone 5 at the Ghanzi sediment hosted Copper-Silver Project in Botswana. The reported drill results are from infill and down dip extensional drilling. Infill drill holes at Zone 5 are 100 x 50 meters apart along a 2.7 km strike length. The Company will use results from the infill drilling to increase confidence in the resource estimate from Inferred to Indicated.

A total of 168 holes have been drilled for an aggregate of 30,062 meters to date in 2012; results from 84 holes have been reported. There are eight diamond drill rigs currently at work on Zones 2, 4, 5 and 6. The drill program planned for 2012 is to discover the extent of mineralization potential at the Ghanzi Project and to increase the confidence of known mineralization through infill drilling.

Yesterday, Hana Mining announced that they agreed to a C$0.82 per share all-cash acquisition by Cupric Canyon Capital LP. Hana and Cupric Canyon Capital jointly announced that they entered into a definitive agreement whereby Cupric agreed to acquire all of the issued and outstanding common shares of Hana (other than the Hana Shares they presently own) through a statutory Plan of Arrangement under the Business Corporations Act (British Columbia).

Hana shareholders will receive C$0.82 in cash for each common share of Hana. This represents a premium of approximately 88 percent to the 20-day volume weighted average price of the Hana Shares on the TSX Venture Exchange as of October 23, 2012. The total consideration payable to Hana shareholders is approximately C$67 million and the Arrangement values Hana's equity at approximately C$82 million. Upon closing of this transaction, Cupric's intention is to advance the Ghanzi project through the design, construction and operational phases of its development.

Hana Mining Ltd. (HMG.V), closed Thursday's trading session at $0.79, up 73.63%, on 9,402,866 volume. The stock's 52-week low/high is $0.30/$2.25.

graphic

The QualityStocks
Company Corner

graphic
graphic

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.25, even with yesterday's close, on 67,063 volume with 19 trades. The stock’s average daily volume over the past 60 days is 112,336, and its 52-week low/high is $0.21/$0.71.

International Stem Cell Corp. reported today that the company's Lifeline Cell Technology subsidiary will commence with sales of its product line through the popular online catalogue of Fisher Scientific, Inc., with the key distinction of being designated as an Encompass Preferred Supplier. This designation places the company in prime position to benefit from the huge amount of business done by Fisher Scientific, the planet's biggest supplier of research supplies and other products supplied, typically to large pharma companies in the life sciences industry via such preferred supplier agreements as here accessed. Fisher has a 350k-strong consumer base and over $12B a year in sales, with the third party e-catalog segment up a whopping 530% to $424M in the last five years alone, this represents a massive sales channel for the high-quality stem cell-based products, specialized cells, and growth media for therapeutic research developed by ISCO's Lifeline Cell Technology subsidiary.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corp's Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs

International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine

International Stem Cell Corp to Participate in Upcoming Investor Conference

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.012, up 20.00%, on 446,500 volume with 11 trades. The stock’s average daily volume over the past 60 days is 225,651, and its 52-week low/high is $0.001/$0.018.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Consorteum Completes Acquisition of Tarsin Inc.

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.71, up 1.43%, on 3,500 volume with 4 trades. The stock’s average daily volume over the past 60 days is 608, and its 52-week low/high is $0.06/$3.15.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring

VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund

VistaGen CEO Issues Update Letter to Stockholders

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $3.90, up 0.26%, on 11,343 volume with 13 trades. The stock’s average daily volume over the past 60 days is 41,964, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

Fisher Scientificís Catalogs to Add International Stem Cell Corp. (ISCO) Lifeline Cell Technology Products

International Stem Cell Corp., a California-based biotech company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, just announced that its subsidiary, Lifeline Cell Technology (LCT), will start selling its products through Fisher Scientific’s online catalog as an Encompass Preferred Supplier.

Large pharmaceutical companies typically buy research supplies and products through preferred supplier agreements. Fisher Scientific, a division of Thermo Fisher Scientific, Inc. (NYSE: TMO), is the world’s largest such supplier to the life science industry with over 350,000 customers and $12 billion in annual sales. Third party e-catalog sales have grown from $26 million in 2006 to $424 million in 2011. As an encompass preferred supplier, International Stem Cell Corporation’s subsidiary gains a promising new sales channel for its cell and media products.

“This is a tremendous opportunity and a testament to the high quality of Life Cell Technology’s products,” emphasized Dr. Simon Craw, ISCO’s Executive Vice President of Business Development. “By working with Fisher Scientific, LCT will be able to reach many more customers that we would otherwise not be able to reach. One of the biggest challenges we faced was the ability to sell into pharmaceutical companies that have preferred supplier agreements. Our inclusion in the Fisher e-catalogs and Encompass Preferred Suppliers list, not only validates LCT’s focus on delivering high quality products but also means these products can now be purchased much more easily by scientists working at the some of the world’s largest life science companies.”

For more information on Thermo Fisher Scientific, visit www.thermofisher.com

For additional information on International Stem Cell Corp., visit www.InternationalStemCell.com

Cardium Therapeutics, Inc. (CXM) Acquisition of To Go Brands Further Taps Growing Supplements Market

The recent acquisition by Cardium Therapeutics, a health sciences and regenerative medicine company, of To Go Brands, a private California-based nutraceutical company, is in line with Cardium’s strategy of accelerating the growth and development of their own MedPodium health supplements platform. MedPodium is Cardium’s portfolio of science-based nutraceuticals, metabolics, and aesthetics, designed to promote healthy lifestyle interests such as enhancing energy, cognition, mood, sleep, weight management, fitness, and aesthetics. The acquisition provides Cardium with a greatly expanded marketing and distribution network, together with an established line of compatible products.

To Go Brands has developed and sells 25 health supplement related products, including 100% natural antioxidant rich drink mixes with organic ingredients, in various forms for easy use, along with capsule-based dietary supplements. Their products are sold online, and in a wide range of retail stores, such as Kroger, Whole Foods, GNC, Hi-Health, Vitamin World, and many others. To Go Brands sales for the first 6 months of 2012 totaled $1.7 million.

The acquisition also brings Cardium an experienced management team with key contacts, and a successful record of developing and taking to market new health products through different channels. The agreement calls for To Go Brands to coordinate Cardium’s MedPodium line, using To Go Brands’ established logistics and distribution capabilities. They will also work with Cardium’s strategic investment in SourceOne Global Partners, a leading supplier of science-based ingredients and proprietary formulas to the national supplement and functional food and beverage industries.

Cardium CEO, Christopher J. Reinhard, commented on the growth of the supplements market: “According to a new industry report, U.S. supplement sales are estimated to total $11.5 billion in 2012 and are projected to reach $15.5 billion by 2017. The success of products like Five Hour Energy® have shown that the nutraceutical space has the potential to generate billion dollar products without the extensive regulatory and other hurdles biologics and pharmaceuticals face.”

For additional information, visit www.CardiumTHX.com

BG Medicine, Inc. (BGMD) to Provide Galectin-3 Testing Services in China via an Agreement with Kindstar Diagnostics

BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics, announced that it has signed an agreement with Kindstar Diagnostics Co. Ltd., the largest esoteric diagnostic testing business in China, enabling Kindstar to offer galectin-3 testing services for heart failure management in China. In the US, the BGM Galectin-3(R) test is cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure.

Kindstar, a company that provides esoteric diagnostic testing services to hospitals and physicians in every province of China and provides laboratory testing services to over 2,000 Chinese hospitals, will offer galectin-3 testing services as part of its growing suite of cardiovascular tests. Kindstar has a broad reach and strong network in the burgeoning diagnostic testing market of China, which is in the process of reforming its health care system under its Healthy China 2020 initiative. While the country works to expand health care coverage for its 1.4 billion citizens, a substantial and increasing segment of the population currently pay out-of-pocket for essential medical services, which provides a ready market for diagnostic testing services like galectin-3 testing.

“We are excited to be partnering with Kindstar, the largest diagnostics lab in China, to further expand the footprint of galectin-3 testing throughout the world,” said Eric Bouvier, President and Chief Executive Officer of BG Medicine. “Cardiovascular disease is one of the most prevalent and debilitating diseases in China, affecting more than 230 million people, and we believe that Kindstar’s galectin-3 testing services will help to provide medical professionals with clinical information on fibrosis formation and cardiac remodeling, which are important biological processes in the development and progression of heart failure, while also helping to manage the costs of expanding health care coverage to more of China’s citizens.”

“Every minute six people in China die from cardiovascular disease, making it imperative that we do what we can to improve the lives of those affected,” said Dr. Shiang Huang, Chief Executive Officer of Kindstar Diagnostics. “We believe that clinically relevant and novel markers like galectin-3 will help medical professionals in China identify patients who are at greatest risk for developing heart failure, which assists us to focus the most attention on those who need it.”

In addition to this agreement with Kindstar in China, BG Medicine has marketing and distribution agreements with leading national and regional testing facilities in the United States, including Health Diagnostics Laboratory, Laboratory Corporation of America, Cleveland Heart Laboratory, Mayo, Atherotech and ARUP. BG Medicine has also partnered with leading diagnostic instrument manufacturers, including Abbott Laboratories, Alere, bioMerieux and Siemens, for the development and commercialization of automated versions of galectin-3 testing.

Dynamic Energy Alliance Corp. (DEAC) Kicks Off Prototyping Phase in Run Up to Commercialization of Organic Compound Recovery from Tires

Dynamic Energy Alliance, the rapidly emerging energy and recycling firm constantly pushing the envelope in applied proprietary recovery and finishing processes which are integrated with the latest technologies for producing high-value end products from waste feedstock, announced initiation of Phase 1 today in a planned four-part process to commercialize the company’s patented organic compound extraction technology.

This prototype phase is being carried out under the non-binding agreement in principle from Oct 11, executed with TKF fractionator system developer, Terpen Kraftig LLC. The company also filed an 8-k with the SEC the same day the non-binding agreement was executed, in order to, in part, fully disclose the agreement with respect to the contemplated license. These are strong moves towards a binding definitive agreement and while the terms of such a deal have yet to be negotiated to satisfaction, the wheels have been set in motion and the prototype phase to validate commercialization will be the key to advancing.

As per the agreement Terpen has finished the prototype design/spec portion of the project and has begun sourcing the hardware needed to pull it off. Both companies will be working hand-in-hand over the next two to four months as fabrication and testing escalate towards a five gallon per day unit that should serve validation purposes quite nicely, proving both the efficacy of the organic compound extraction method and the technology’s scalability in one fell swoop.

Everything is happening right on schedule according to the company’s implementation calendar, which has Phase 2 (scale-up phase) slated for Q1 next year, after the completion of which DEAC will be set for the pilot phase (Phase 3 is scheduled for Q1 2014 or asap). The pilot phase will consist of a demonstration plant that will then serve not only as a viable 50 gallon/day processor, but also as a benchmarking framework for the company in the run up to the Phase 4, modular, 25 ton/day pyrolysis plant which will be operated by DEAC and used to showcase/syndicate the technology to interested third parties.

The only real challenge this effort will face off with will be funding procurement for key aspects of certain phases and thus it is imperative that DEAC obtain the kind of market exposure deserving of this revolutionary method for not only breaking down waste products like old tires into viable organic compounds or other end products, but also reducing the emissions typically associated with traditional processing dramatically. This multi-phase roll out dovetails very well with the company’s larger strategy to build Energy Campuses, characterized by low fixed cost and recurring revenues over the long-term.

The successful merger of advanced existing technologies and the kind of proprietary recovery/finishing processes as those developed by DEAC and others promises to usher in a new paradigm for the energy loop, especially when it comes to products like tires. The company’s highly-scalable technology, as well as commercial development “Energy Campus” strategy, should prove to be a massive springboard for the shift towards a greener tomorrow and shareholders can rest assured that this phased evolution of the systems and engineering will translate into a stable revenue driver via eventual commercialization. It will be interesting to see how third party engagements go in the next year or so as DEAC approaches the larger system implementations.

Chairman of DEAC, Charles R. Cronin, Jr., noted how important this prototype phase was to the eventual success of the technology’s commercialization and assured investors that the four-part plan to complete a working production environment was well underway, with Terpen taking the lead to advance this phase. Cronin seemed really pleased with the show of good faith from Terpen and confirmed that the company was hard at work taking all the necessary steps to realize the full potential of the agreement.

More information on Dynamic Energy Alliance Corp. can be had at the following link: www.DynamicEnergyAlliance.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

PennyStockSpy
(TALN)

2.

OTCPicks
(EVXA)

3.

PennyTrader Publisher
(EXTO)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251